Independent directory Public ClinicalTrials.gov records United States
Clear filters

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 18, 2026, 6:55 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 740 matching trials from the live ClinicalTrials.gov search.
Conditions
Crohn Disease, Colitis, Ulcerative
Interventions
Ustekinumab, Other Biologic Therapies
Drug
Lead sponsor
Janssen Scientific Affairs, LLC
Industry
Eligibility
18 Years and older
Enrollment
1,536 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2030
U.S. locations
1
States / cities
Houston, Texas
Conditions
Alzheimer Disease, Early Onset
Interventions
Neuronavigation-guided single-element focused ultrasound transducer, Lumason, Magnetic Resonance Imaging (MRI) with or without gadolinium contrast agents, Positron Emission Tomography (PET), Amyvid, MK-6240, Dotarem, Blood draw, UR5e, Urine test
Device · Drug · Other + 2 more
Lead sponsor
Columbia University
Other
Eligibility
50 Years and older
Enrollment
6 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2027 – 2028
U.S. locations
1
States / cities
New York, New York
Conditions
Postoperative Pain
Interventions
Acetaminophen or Placebo
Drug
Lead sponsor
Brooke Army Medical Center
Federal
Eligibility
18 Years to 90 Years
Enrollment
55 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2013 – 2018
U.S. locations
1
States / cities
San Antonio, Texas
Conditions
Hip or Knee Replacement
Interventions
'M'-Technique®, Guided Imagery, Standard of Care
Other
Lead sponsor
Saint Clare's Health System
Other
Eligibility
18 Years and older
Enrollment
225 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2012
U.S. locations
1
States / cities
Denville, New Jersey
Conditions
Solid and Hematological Malignancies
Interventions
Genetically engineered T Cell Receptors
Genetic
Lead sponsor
Adaptimmune
Industry
Eligibility
18 Years and older
Enrollment
2 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
2
States / cities
Nashville, Tennessee • Houston, Texas
Conditions
Stem Cell Transplantation, Graft vs Host Disease
Interventions
Budesonide, Fluconazole, Voriconazole, Micafungin
Drug
Lead sponsor
National Institutes of Health Clinical Center (CC)
NIH
Eligibility
13 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2020
U.S. locations
1
States / cities
Bethesda, Maryland
Conditions
Non-Hodgkin Lymphoma, Diffuse Large B-cell Lymphoma, Mantle Cell Lymphoma, Follicular Lymphoma, Peripheral T-cell Lymphoma
Interventions
Carfilzomib, Belinostat
Drug
Lead sponsor
Massachusetts General Hospital
Other
Eligibility
18 Years and older
Enrollment
19 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2018
U.S. locations
3
States / cities
Boston, Massachusetts
Conditions
KCNT1-Related Epilepsy
Interventions
No Intervention
Other
Lead sponsor
Biogen
Industry
Eligibility
0 Years to 50 Years
Enrollment
35 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Rochester, New York
Conditions
Ovarian Neoplasms, Peritoneal Neoplasms, Fallopian Tube Neoplasms
Interventions
Trabectedin, DOXIL, Dexamethasone
Drug
Lead sponsor
Janssen Research & Development, LLC
Industry
Eligibility
18 Years and older · Female only
Enrollment
581 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
75
States / cities
Birmingham, Alabama • Phoenix, Arizona • Scottsdale, Arizona + 72 more
Active, not recruiting No phase listed Observational

ADH1 and ADH2 Disease Monitoring Study (DMS)

NCT05227287
Conditions
Autosomal Dominant Hypocalcemia
Interventions
Not listed
Lead sponsor
Calcilytix Therapeutics, Inc., a BridgeBio company
Industry
Eligibility
Up to 90 Years
Enrollment
95 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2022 – 2028
U.S. locations
9
States / cities
Oakland, California • Aurora, Colorado • Jacksonville, Florida + 6 more
Conditions
Laparoscopic Colorectal Resection
Interventions
TAP block, Epidural, Paravertebral block, Acetaminophen 1g IV, Dexamethasone 4mg, Midazolam up to 2mg, Propofol 1-2.5 mg/kg, Sevoflurane to keep a bispectral index of between 40-60, Local infiltration with 10 mL of plain ropivacaine 0.25%, Lidocaine, Epinephrine, Hydromorphone
Procedure · Drug
Lead sponsor
Duke University
Other
Eligibility
18 Years and older
Enrollment
17 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
Durham, North Carolina
Conditions
Recurrent Breast Cancer, Stage IA Breast Cancer, Stage IB Breast Cancer, Stage II Breast Cancer, Stage IIIA Breast Cancer, Stage IIIB Breast Cancer, Stage IIIC Breast Cancer
Interventions
omega-3 fatty acid supplement, Placebo, Clinical assessments, Assessment of therapy complications, Magnetic Resonance Imaging, Correlative/special studies
Dietary Supplement · Other · Procedure
Lead sponsor
Ohio State University Comprehensive Cancer Center
Other
Eligibility
18 Years and older · Female only
Enrollment
44 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2014
U.S. locations
1
States / cities
Columbus, Ohio
Conditions
Shock, Septic
Interventions
Lactated Ringer, Normal Saline, Plasma-lyte
Drug
Lead sponsor
Children's Hospital of Philadelphia
Other
Eligibility
2 Months to 17 Years
Enrollment
9,041 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2026
U.S. locations
22
States / cities
Davis, California • Los Angeles, California • San Francisco, California + 19 more
Conditions
Sars-CoV2, Acute Respiratory Distress Syndrome, COVID-19
Interventions
Mesenchymal Stromal Cells, Supportive Care
Biological · Other
Lead sponsor
Baylor College of Medicine
Other
Eligibility
18 Years and older
Enrollment
28 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2023
U.S. locations
1
States / cities
Houston, Texas
Conditions
Pelvic Pain
Interventions
Acetaminophen 1000mg PO, IV Acetaminophen 1000mg, IV Placebo, PO Placebo
Drug · Other
Lead sponsor
Montefiore Medical Center
Other
Eligibility
16 Years to 50 Years · Female only
Enrollment
140 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2026 – 2027
U.S. locations
1
States / cities
The Bronx, New York
Active, not recruiting Phase 3 Interventional Results available

Phase 3 Study of Pelabresib (CPI-0610) in Myelofibrosis (MF) (MANIFEST-2)

NCT04603495
Conditions
Myelofibrosis, Primary Myelofibrosis, Post-polycythemia Vera Myelofibrosis, Post-essential Thrombocythemia Myelofibrosis
Interventions
Pelabresib, Ruxolitinib, Placebo
Drug
Lead sponsor
Novartis Pharmaceuticals
Industry
Eligibility
18 Years and older
Enrollment
430 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2027
U.S. locations
20
States / cities
Birmingham, Alabama • Chandler, Arizona • La Jolla, California + 14 more
Conditions
Sarcoma, Refractory Sarcoma
Interventions
Pazopanib, Irinotecan, Temozolomide
Drug
Lead sponsor
University of California, San Francisco
Other
Eligibility
6 Years to 30 Years
Enrollment
16 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2020
U.S. locations
3
States / cities
Oakland, California • San Francisco, California • Boston, Massachusetts
Completed Not applicable Interventional Accepts healthy volunteers

Modulating Glucose Tolerance With Dietary Tyrosine

NCT03872557
Conditions
Glucose Tolerance
Interventions
Tyrosine (TYR) Supplementation
Dietary Supplement
Lead sponsor
Columbia University
Other
Eligibility
18 Years to 65 Years
Enrollment
10 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
1
States / cities
New York, New York
Conditions
Gout
Interventions
Pegloticase, Methotrexate (MTX), Standard Gout Flare Prophylaxis, Infusion Reaction (IR) Prophylaxis, Folic Acid
Biological · Drug · Dietary Supplement
Lead sponsor
Amgen
Industry
Eligibility
18 Years to 65 Years
Enrollment
14 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018 – 2020
U.S. locations
6
States / cities
Anchorage, Alaska • Glendale, Arizona • Mesa, Arizona + 3 more
Conditions
Acute Lymphoblastic Leukemia
Interventions
JCAR015
Genetic
Lead sponsor
Juno Therapeutics, a Subsidiary of Celgene
Industry
Eligibility
18 Years and older
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2016 – 2021
U.S. locations
4
States / cities
Chicago, Illinois • Baltimore, Maryland • St Louis, Missouri + 1 more
Conditions
Multiple Myeloma
Interventions
High-Dose Melphalan HCL for Injection (Propylene Glycol-Free), Autologous Transplantation
Drug · Other
Lead sponsor
Acrotech Biopharma Inc.
Industry
Eligibility
Up to 70 Years
Enrollment
61 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2014
U.S. locations
6
States / cities
Chicago, Illinois • Fairway, Kansas • Worcester, Massachusetts + 3 more
Conditions
Food Intake
Interventions
Placebo spray, Diltiazem
Other · Drug
Lead sponsor
Pennington Biomedical Research Center
Other
Eligibility
18 Years to 60 Years
Enrollment
12 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Baton Rouge, Louisiana
Conditions
Neuroendocrine Tumors, Neoplasms, Cancer, Tumors
Interventions
TAS-102, Temozolomide, Filgrastim, Pegfilgrastim
Drug
Lead sponsor
University of Wisconsin, Madison
Other
Eligibility
18 Years and older
Enrollment
18 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2017 – 2022
U.S. locations
1
States / cities
Madison, Wisconsin
Completed Phase 2 Interventional Accepts healthy volunteers

Anthrax AV7909 Boost Evaluation Study

NCT05997264
Conditions
Anthrax
Interventions
AV7909 Full Dose (0.5 mL), AV7909 Half Dose (0.25 mL), Placebo: Sodium Chloride Injection, USP 0.9% (0.5 mL), Placebo: Sodium Chloride Injection, USP 0.9% (0.25 mL)
Biological
Lead sponsor
Biomedical Advanced Research and Development Authority
Federal
Eligibility
18 Years to 65 Years
Enrollment
220 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023 – 2026
U.S. locations
7
States / cities
Hickory, North Carolina • Salisbury, North Carolina • Statesville, North Carolina + 3 more